Akorn shares remain attractively valued, says Piper Jaffray Piper Jaffray believes shares of Akorn remain attractively valued despite the recent strength. The firm expects gross margin expansion from recent acquisitions and keeps an Overweight rating on the stock with a $33 price target.
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.